TELA · Company research
TELA Bio, Inc. Common Stock (TELA): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
17records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Stock replaces cash pay for TELA Bio (TELA) director in 19,801-share award. - Stock Titan | Stock replaces cash pay for TELA Bio (TELA) director in 19,801-share award. Stock Titan | View source ↗ | Stock Titan | Oct 19, 2026 | neutral | 0 | 0.6 |
| TELA Bio (TELA) director William J. Plovanic receives 16,089 shares instead of cash compensation. - Stock Titan | TELA Bio (TELA) director William J. Plovanic receives 16,089 shares instead of cash compensation. Stock Titan | View source ↗ | Stock Titan | Oct 19, 2026 | neutral | 0 | 0.6 |
| TELA Bio (TELA) Stock Sees Fair Value Cut As Analysts Weigh New Leadership Risks - Yahoo Finance | TELA Bio (TELA) Stock Sees Fair Value Cut As Analysts Weigh New Leadership Risks Yahoo Finance | View source ↗ | Yahoo Finance | Oct 19, 2026 | neutral | 0 | 0.6 |
| TELA Bio Regains Nasdaq Compliance, Securing Listing Status - The Globe and Mail | TELA Bio Regains Nasdaq Compliance, Securing Listing Status The Globe and Mail | View source ↗ | The Globe and Mail | Oct 7, 2026 | neutral | 0 | 0.6 |
| TELA Bio Announces 510(k) Clearance for Liora™ Monofilament Scaffold for Soft Tissue Reinforcement | TELA Bio announced FDA 510(k) clearance for its Liora Monofilament Scaffold, a fully resorbable surgical mesh device for soft tissue reinforcement. Liora is the first fully resorbable synthetic product in the company's portfolio to be designed and produced in-house at its ISO 8 certified cleanroom in Malvern, PA, expanding TELA Bio's soft tissue reconstruction market footprint. | View source ↗ | GlobeNewswire Inc. | Oct 5, 2026 | bullish | 1 | 1 |
| The FDA cleared a surgical mesh designed to be fully absorbed by the body. - Stock Titan | The FDA cleared a surgical mesh designed to be fully absorbed by the body. Stock Titan | View source ↗ | Stock Titan | Oct 5, 2026 | neutral | 0 | 0.6 |
| Tela Bio director Capper acquires $78,442 in company stock - Investing.com | Tela Bio director Capper acquires $78,442 in company stock Investing.com | View source ↗ | Investing.com | Sep 16, 2026 | neutral | 0 | 0.6 |
| TELA Bio Inc. (TELA) Edges Higher on Renewed Buying Interest Near Key Support Zone - Short Term Trading Ideas - https://www.siam.in/ | TELA Bio Inc. (TELA) Edges Higher on Renewed Buying Interest Near Key Support Zone - Short Term Trading Ideas https://www.siam.in/ | View source ↗ | https://www.siam.in/ | Sep 3, 2026 | neutral | 0 | 0.6 |
| TELA Bio is cutting about 20% of its headcount to save $17 million a year - Stock Titan | TELA Bio is cutting about 20% of its headcount to save $17 million a year Stock Titan | View source ↗ | Stock Titan | Aug 31, 2026 | neutral | 0 | 0.6 |
| Tela Bio CEO Heather Getz buys $8,311 in company stock - Investing.com | Tela Bio CEO Heather Getz buys $8,311 in company stock Investing.com | View source ↗ | Investing.com | Aug 26, 2026 | neutral | 0 | 0.6 |
| Insider Purchase: Chief Executive Officer of $TELA Buys 15,000 Shares - Quiver Quantitative | Insider Purchase: Chief Executive Officer of $TELA Buys 15,000 Shares Quiver Quantitative | View source ↗ | Quiver Quantitative | Aug 17, 2026 | neutral | 0 | 0.6 |
| Analysts Have Been Trimming Their TELA Bio, Inc. (NASDAQ:TELA) Price Target After Its Latest Report - Simply Wall Street | Analysts Have Been Trimming Their TELA Bio, Inc. (NASDAQ:TELA) Price Target After Its Latest Report Simply Wall Street | View source ↗ | Simply Wall Street | Aug 13, 2026 | neutral | 0 | 0.6 |
| TELA Bio, Inc. Stock 12‑Month Price Target Cut to $2.1, Implies 126% Upside - TradingView | TELA Bio, Inc. Stock 12‑Month Price Target Cut to $2.1, Implies 126% Upside TradingView | View source ↗ | TradingView | Aug 11, 2026 | neutral | 0 | 0.6 |
| TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire | TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire | View source ↗ | GlobeNewswire | Aug 5, 2026 | neutral | 0 | 0.6 |
| Tela Bio names new CEO as co-founder exits after 14 years - The Business Journals | Tela Bio names new CEO as co-founder exits after 14 years The Business Journals | View source ↗ | The Business Journals | Aug 4, 2026 | neutral | 0 | 0.6 |
| TELA Forecast — Price Target — Prediction for 2027 - TradingView | TELA Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 25, 2026 | neutral | 0 | 0.6 |
| TELA Bio, Inc. (TELA) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance | TELA Bio, Inc. (TELA) Reports Q4 Loss, Lags Revenue Estimates Yahoo Finance | View source ↗ | Yahoo Finance | Mar 24, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.